Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma

Sanjal H. Desai; Raphael Mwangi; Alexandra N. Smith; Matthew J. Maurer; Umar Farooq; Rebecca L. King; James R Cerhan; Andrew L. Feldman; Thomas M. Habermann; Carrie A. Thompson; Yucai Wang; Stephen M. Ansell; Thomas E. Witzig; Grzegorz S. Nowakowski

doi:10.1002/hon.3098

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma

Sanjal H. Desai, Raphael Mwangi, Alexandra N. Smith, Matthew J. Maurer, Umar Farooq, Rebecca L. King, James R Cerhan, Andrew L. Feldman, Thomas M. Habermann, Carrie A. Thompson, Yucai Wang, Stephen M. Ansell, Thomas E. Witzig, Grzegorz S. Nowakowski

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

Abstract

Activated B cell (ABC) type diffuse large B cell lymphoma (DLBCL), double hit lymphoma (DHL) and double expressor lymphoma (DEL) have poor outcomes to frontline R-CHOP but impact of these molecular features on outcomes of relapsed/refractory (R/R) disease is not well-characterized. We evaluated the association of diagnostic cell of origin (COO), double hit and double expressor status with overall survival after first relapse in DLBCL patients who were enrolled into the Molecular Epidemiology Resource (MER) cohort. COO was available from immunohistochemistry (IHC) using Hans criteria or gene expression profiling (GEP) (Nanostring) on the diagnostic FFPE biopsy. Of 373 pts with R/R DLBCL, 278 had COO by IHC: 152 were GCB, 107 were non-GCB. One hundred and fourty had COO by GEP: 44 were ABC, 65 were GCB and 13 were unclassifiable. Nineteen out of 163 (12%) were DHL; 30 out of 135 (22%) had DEL. COO, either by IHC (2 years OS GCB: 45% [CI₉₅: 38–54] vs. non-GCB: 44% [CI₉₅:36–55], p > 0.05) or GEP (2 years OS ABC: 42% [CI₉₅: 29–59] vs. GCB: 40% [CI₉₅: 30–54], p > 0.05), was not associated with difference in OS. DHL (2 years OS 16 [CI₉₅:6–45] vs. 45% [CI₉₅: 34–59], p < 0.01) and DEL (2 years OS 33% [CI₉₅: 20–56], vs. 50% [CI₉₅: 41–60], p < 0.05) had lower OS than non-DHL and non-DEL/non-DHL counterparts, respectively. COO by IHC or GEP was not associated with OS in R/R DLBCL while DHL and DEL were adverse prognostic markers in DLBCL at first relapse.

Original language	English (US)
Pages (from-to)	39-49
Number of pages	11
Journal	Hematological Oncology
Volume	41
Issue number	1
DOIs	https://doi.org/10.1002/hon.3098
State	Published - Feb 2023

Bibliographical note

Funding Information:
This work was supported by the National Cancer Institute, National Institutes of Health (P50 CA97274 and U01 CA195568).

Publisher Copyright:
© 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.

Keywords

ABC
DEL
DHL
DLBCL
GCB

PubMed: MeSH publication types

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1002/hon.3098License: CC BY-NC

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hon.3098License: CC BY-NC

Find It

Find It at U of M Libraries

Cite this

Desai, S. H., Mwangi, R., Smith, A. N., Maurer, M. J., Farooq, U., King, R. L., Cerhan, J. R., Feldman, A. L., Habermann, T. M., Thompson, C. A., Wang, Y., Ansell, S. M., Witzig, T. E., & Nowakowski, G. S. (2023). Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma. Hematological Oncology, 41(1), 39-49. https://doi.org/10.1002/hon.3098

@article{a10e44bfc10444b4ade58691abb7cf77,

title = "Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma",

abstract = "Activated B cell (ABC) type diffuse large B cell lymphoma (DLBCL), double hit lymphoma (DHL) and double expressor lymphoma (DEL) have poor outcomes to frontline R-CHOP but impact of these molecular features on outcomes of relapsed/refractory (R/R) disease is not well-characterized. We evaluated the association of diagnostic cell of origin (COO), double hit and double expressor status with overall survival after first relapse in DLBCL patients who were enrolled into the Molecular Epidemiology Resource (MER) cohort. COO was available from immunohistochemistry (IHC) using Hans criteria or gene expression profiling (GEP) (Nanostring) on the diagnostic FFPE biopsy. Of 373 pts with R/R DLBCL, 278 had COO by IHC: 152 were GCB, 107 were non-GCB. One hundred and fourty had COO by GEP: 44 were ABC, 65 were GCB and 13 were unclassifiable. Nineteen out of 163 (12%) were DHL; 30 out of 135 (22%) had DEL. COO, either by IHC (2 years OS GCB: 45% [CI95: 38–54] vs. non-GCB: 44% [CI95:36–55], p > 0.05) or GEP (2 years OS ABC: 42% [CI95: 29–59] vs. GCB: 40% [CI95: 30–54], p > 0.05), was not associated with difference in OS. DHL (2 years OS 16 [CI95:6–45] vs. 45% [CI95: 34–59], p < 0.01) and DEL (2 years OS 33% [CI95: 20–56], vs. 50% [CI95: 41–60], p < 0.05) had lower OS than non-DHL and non-DEL/non-DHL counterparts, respectively. COO by IHC or GEP was not associated with OS in R/R DLBCL while DHL and DEL were adverse prognostic markers in DLBCL at first relapse.",

keywords = "ABC, DEL, DHL, DLBCL, GCB",

author = "Desai, {Sanjal H.} and Raphael Mwangi and Smith, {Alexandra N.} and Maurer, {Matthew J.} and Umar Farooq and King, {Rebecca L.} and Cerhan, {James R} and Feldman, {Andrew L.} and Habermann, {Thomas M.} and Thompson, {Carrie A.} and Yucai Wang and Ansell, {Stephen M.} and Witzig, {Thomas E.} and Nowakowski, {Grzegorz S.}",

note = "Funding Information: This work was supported by the National Cancer Institute, National Institutes of Health (P50 CA97274 and U01 CA195568). Publisher Copyright: {\textcopyright} 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.",

year = "2023",

month = feb,

doi = "10.1002/hon.3098",

language = "English (US)",

volume = "41",

pages = "39--49",

journal = "Hematological Oncology",

issn = "0278-0232",

publisher = "John Wiley and Sons Ltd",

number = "1",

}

TY - JOUR

T1 - Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma

AU - Desai, Sanjal H.

AU - Mwangi, Raphael

AU - Smith, Alexandra N.

AU - Maurer, Matthew J.

AU - Farooq, Umar

AU - King, Rebecca L.

AU - Cerhan, James R

AU - Feldman, Andrew L.

AU - Habermann, Thomas M.

AU - Thompson, Carrie A.

AU - Wang, Yucai

AU - Ansell, Stephen M.

AU - Witzig, Thomas E.

AU - Nowakowski, Grzegorz S.

N1 - Funding Information: This work was supported by the National Cancer Institute, National Institutes of Health (P50 CA97274 and U01 CA195568). Publisher Copyright: © 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.

PY - 2023/2

Y1 - 2023/2

N2 - Activated B cell (ABC) type diffuse large B cell lymphoma (DLBCL), double hit lymphoma (DHL) and double expressor lymphoma (DEL) have poor outcomes to frontline R-CHOP but impact of these molecular features on outcomes of relapsed/refractory (R/R) disease is not well-characterized. We evaluated the association of diagnostic cell of origin (COO), double hit and double expressor status with overall survival after first relapse in DLBCL patients who were enrolled into the Molecular Epidemiology Resource (MER) cohort. COO was available from immunohistochemistry (IHC) using Hans criteria or gene expression profiling (GEP) (Nanostring) on the diagnostic FFPE biopsy. Of 373 pts with R/R DLBCL, 278 had COO by IHC: 152 were GCB, 107 were non-GCB. One hundred and fourty had COO by GEP: 44 were ABC, 65 were GCB and 13 were unclassifiable. Nineteen out of 163 (12%) were DHL; 30 out of 135 (22%) had DEL. COO, either by IHC (2 years OS GCB: 45% [CI95: 38–54] vs. non-GCB: 44% [CI95:36–55], p > 0.05) or GEP (2 years OS ABC: 42% [CI95: 29–59] vs. GCB: 40% [CI95: 30–54], p > 0.05), was not associated with difference in OS. DHL (2 years OS 16 [CI95:6–45] vs. 45% [CI95: 34–59], p < 0.01) and DEL (2 years OS 33% [CI95: 20–56], vs. 50% [CI95: 41–60], p < 0.05) had lower OS than non-DHL and non-DEL/non-DHL counterparts, respectively. COO by IHC or GEP was not associated with OS in R/R DLBCL while DHL and DEL were adverse prognostic markers in DLBCL at first relapse.

AB - Activated B cell (ABC) type diffuse large B cell lymphoma (DLBCL), double hit lymphoma (DHL) and double expressor lymphoma (DEL) have poor outcomes to frontline R-CHOP but impact of these molecular features on outcomes of relapsed/refractory (R/R) disease is not well-characterized. We evaluated the association of diagnostic cell of origin (COO), double hit and double expressor status with overall survival after first relapse in DLBCL patients who were enrolled into the Molecular Epidemiology Resource (MER) cohort. COO was available from immunohistochemistry (IHC) using Hans criteria or gene expression profiling (GEP) (Nanostring) on the diagnostic FFPE biopsy. Of 373 pts with R/R DLBCL, 278 had COO by IHC: 152 were GCB, 107 were non-GCB. One hundred and fourty had COO by GEP: 44 were ABC, 65 were GCB and 13 were unclassifiable. Nineteen out of 163 (12%) were DHL; 30 out of 135 (22%) had DEL. COO, either by IHC (2 years OS GCB: 45% [CI95: 38–54] vs. non-GCB: 44% [CI95:36–55], p > 0.05) or GEP (2 years OS ABC: 42% [CI95: 29–59] vs. GCB: 40% [CI95: 30–54], p > 0.05), was not associated with difference in OS. DHL (2 years OS 16 [CI95:6–45] vs. 45% [CI95: 34–59], p < 0.01) and DEL (2 years OS 33% [CI95: 20–56], vs. 50% [CI95: 41–60], p < 0.05) had lower OS than non-DHL and non-DEL/non-DHL counterparts, respectively. COO by IHC or GEP was not associated with OS in R/R DLBCL while DHL and DEL were adverse prognostic markers in DLBCL at first relapse.

KW - ABC

KW - DEL

KW - DHL

KW - DLBCL

KW - GCB

UR - http://www.scopus.com/inward/record.url?scp=85141503439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141503439&partnerID=8YFLogxK

U2 - 10.1002/hon.3098

DO - 10.1002/hon.3098

M3 - Article

C2 - 36305717

AN - SCOPUS:85141503439

SN - 0278-0232

VL - 41

SP - 39

EP - 49

JO - Hematological Oncology

JF - Hematological Oncology

IS - 1

ER -

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this